Immune Therapy Shows Early Promise for Advanced Leukemia, Memorial Sloan-Kettering Cancer Center Study

An experimental therapy that targets the immune system might offer a new way to treat an often deadly form of adult leukemia, a preliminary study suggests. The research involved only five adults with recurrent B-cell acute lymphoblastic leukemia (ALL), a cancer of the blood and bone marrow. ALL progresses quickly, and patients can die within weeks if untreated. The typical first treatment is three separate phases of chemotherapy drugs.

MORE ON THIS TOPIC